Introduction {#s1}
============

Telomeres are nucleoprotein structures assembled at the extremities of eukaryotic chromosomes that protect chromosome ends. By doing so, telomeres prevent chromosome ends from being recognized as sites of DNA damage, protecting them from degradation and inappropriate recombination events due to erroneous activation of DNA repair pathways (Doksani and de Lange, [@B32]). Telomeres are also required for the complete replication of genomic DNA. Indeed, eukaryotic chromosomes are deemed to progressively shorten during cell divisions due to limitations of the semiconservative DNA replication machinery which is unable to fully replicate the extremities of linear DNA, a phenomenon known as the "end replication problem" (Hug and Lingner, [@B49]; Jain and Cooper, [@B51]). In the absence of maintenance mechanisms chromosome ends erode, telomeres become dysfunctional and are recognized as sites of DNA damage, leading to cellular senescence or rampant genome instability and apoptosis (Deng et al., [@B25]). In most eukaryotes, telomeres compensate for the end replication problem by recruiting the reverse transcriptase telomerase. Telomerase uses the 3′ end of chromosomes as primer to elongate chromosome ends by reverse transcription of the template region of its RNA moiety and in concerted action with the DNA replication machinery (Greider and Blackburn, [@B43]; Hug and Lingner, [@B49]). While telomerase activity is detected in some highly proliferative tissues, not sufficient amount of telomerase is expressed in human somatic cells which enter replicative senescence upon a defined number of cell divisions due to telomere erosion (Allsopp et al., [@B2]). Telomerase inactivation acts as a tumor suppressor mechanism as re-expression of this enzyme in human fibroblasts allows to bypass senescence, leading to cellular immortalization (Bodnar et al., [@B13]). Accordingly, 90% of human cancers reactivate telomerase activity, resulting in stabilized telomere length (Kim et al., [@B54]). For the reasons mentioned above, functional telomeres are essential to genome integrity and cell viability.

In order to exert their functions, telomeres rely on a highly conserved DNA structure which consists of a variable number of telomeric repeats (TTAGGG~n~ in mammalian cells) followed by a single-stranded G-rich 3′ overhang. Electron microscopy and super-resolution fluorescence imaging have shown that telomeric DNA forms higher order structures where the 3′ single-stranded overhang invades the homologous double-stranded region forming a telomeric loop (T-loop) (Griffith et al., [@B44]; Doksani et al., [@B33]). T-loop formation is believed to sequester the 3′ end of chromosomes, thereby preventing its recognition by the DNA damage machinery (de Lange, [@B23]; Doksani et al., [@B33]). Indeed, while essential component of telomeres, 3′ overhang is also a general feature of DNA double strand breaks (DSBs). Functional telomeres thus enable the cell to discriminate the natural chromosome ends from the harmful DSBs.

Telomeric DNA acts as docking site for telomere binding proteins which regulate telomere homeostasis and mediate telomere functions (de Lange, [@B22]). In mammalian cells, the protein complex shelterin is recruited at telomeres through the direct binding of its subunits TRF1 and TRF2 to the double-stranded telomeric DNA (Palm and de Lange, [@B67]). Telomere-bound TRF1 and TRF2 allow the recruitment of the other shelterin components TIN2, the TPP1/POT1 heterodimer, and Rap1 to chromosome ends (Sfeir and de Lange, [@B81]). At telomeres, shelterin proteins mediate distinct functions: TRF2 is required for T-loop formation and maintenance (Doksani et al., [@B33]), and for repression of ATM-mediated DNA damage response (DDR) as well as non-homologous end joining (NHEJ) (Karlseder et al., [@B53]; Denchi and de Lange, [@B24]; Palm and de Lange, [@B67]). TRF1 has a pivotal role in controlling replication of telomeric DNA (Sfeir et al., [@B82]; Zimmermann et al., [@B94]) while POT1 associates with TPP1 to bind the single-stranded 3′ overhang and repress ATR-mediated DDR by preventing the recruitment of replication protein A (RPA) (Denchi and de Lange, [@B24]). TIN2 is essential to the overall integrity of the shelterin complex as it links TPP1/POT1 heterodimer to TRF1 and TRF2, and stabilizes TRF1 and TRF2 association to telomeric DNA (Takai et al., [@B85]; Frescas and de Lange, [@B38],[@B39]). Rap1 interacts with TRF2 but its role in telomere biology is still unclear (Kabir et al., [@B52]).

A conserved feature of telomeres is their enrichment in heterochromatic marks. Human and mouse subtelomeres are heavily methylated through the activity of DNA methyltransferases DNMT1, DNMT3a, and DNMT3b (Gonzalo et al., [@B42]; Schoeftner and Blasco, [@B79]). Chromatin of mammalian telomeres is also under-acetylated and enriched in histone H3 tri-methylated at lysine 9 (H3K9me3) and H4K20me3 (Benetti et al., [@B11]). These posttranslational modifications are mediated by the histone methyltransferases (HMT) Suv39h and Suv4-20h. Loss of HMTs or DNMs results in over-elongated telomeres, indicating the important role of telomeric chromatin in telomere homeostasis and stability (Schoeftner and Blasco, [@B79]). Consistent with the highly conserved compacted state of chromosome ends, earlier studies have shown that reporter genes integrated in proximity to yeast, flies, and mammalian telomeres are transcriptionally silenced (Baur et al., [@B10]; Koering et al., [@B55]; Rusche et al., [@B76]; Mason et al., [@B62]), a phenomenon called "telomere position effect" or TPE.

In stark contrast with these findings and in defiance of the longstanding belief that chromosome ends are transcriptionally silenced, recent evidence has shown that telomeres are transcribed by RNA polymerase II, giving rise to a class of long noncoding RNAs containing telomeric repeats called TERRA (Azzalin et al., [@B7]; Schoeftner and Blasco, [@B78]). TERRA molecules have been detected in a variety of organisms, including yeast, zebrafish, mouse and human, and are believed to actively participate in the mechanisms regulating telomere homeostasis and telomere function (Luke et al., [@B59]; Schoeftner and Blasco, [@B78]). TERRA transcripts have been involved in the regulation of telomerase, formation of heterochromatin at telomeres and proper capping of chromosome ends. Nevertheless, the mechanisms of action of telomeric noncoding RNAs remain largely to be elucidated. In this review, we discuss recent evidence on the emerging role of TERRA acting at the interface between telomeric DNA and telomere binding proteins to regulate telomere biology and genome stability.

Telomeric repeat-containing RNA TERRA in telomere biology
=========================================================

TERRA molecules are transcribed from the subtelomeric regions toward the chromosome ends and consist of subtelomeric-derived sequences and G-rich telomeric repeats (Azzalin et al., [@B7]; Schoeftner and Blasco, [@B78]). TERRA promoter regions have been identified at CpG islands present in a subset of human telomeres in proximity to their telomeric repeats tract. Consistently, DNA methylation at subtelomeric regions generally associates with decreased expression of TERRA (Yehezkel et al., [@B91]; Nergadze et al., [@B64]; Ng et al., [@B65]; Farnung et al., [@B35]). Very recently, a second class of TERRA promoters located 5--10 kilobases away from the telomeric repeats of 10 distinct human telomeres have been identified (Porro et al., [@B70]). The presence of different types of promoters likely contributes to the length heterogeneity of TERRA transcripts. Several lines of evidence indicate that modifications of the heterochromatic state of chromosome ends regulate the expression of TERRA (Azzalin and Lingner, [@B5]; Schoeftner and Blasco, [@B78]; Caslini et al., [@B16]; Iglesias et al., [@B50]; Arnoult et al., [@B3]). The mechanisms regulating TERRA expression and TERRA biogenesis have been recently reviewed elsewhere and will not be covered in this review (Azzalin and Lingner, [@B6]; Cusanelli and Chartrand, [@B19]; Maicher et al., [@B61]). Interestingly, while TERRA transcription has been detected from all human and yeast telomeres analyzed so far, a recent study indicates that TERRA is mainly transcribed from only two telomeres in mouse (de Silanes et al., [@B31]). While it cannot be formerly excluded that telomeric RNAs containing only telomeric repeats are also expressed in mouse, this study reveals that TERRA transcribed from a single telomere can associate with multiple chromosome ends. This suggests that TERRA can act *in trans* in mammalian cells and further supports the view of TERRA as an essential player for the overall maintenance of telomeres and/or telomere function (de Silanes et al., [@B31]). In yeast, live cell imaging experiments have shown that TERRA molecules preferentially localize with their telomere of origin during S phase (Cusanelli et al., [@B20]). In this cellular context, it has been proposed that TERRA expression participates in telomerase-mediated re-lengthening of the TERRA transcribing telomere (see below) (Cusanelli et al., [@B20]). Less is known on the dynamics of TERRA localization in human cells where TERRA transcripts associate with only a subset of chromosome ends at a given time (Azzalin et al., [@B7]; Lai et al., [@B56]), while a fraction of telomeric RNAs also resides within the nucleoplasm (Porro et al., [@B72]), suggesting that TERRA molecules are not constitutively associated with telomeres.

How do TERRA transcripts associate with chromosome ends? Depletion of components of the nonsense mediated RNA decay (NMD) pathway or members of the heterogeneous nuclear ribonucleoprotein family (hnRNPs) which bind TERRA, increases localization of TERRA at chromosome ends without affecting its overall levels or stability (Azzalin et al., [@B7]; Lopez de Silanes et al., [@B57]). These findings suggest that TERRA molecules are actively displaced from telomeres and thus may be recruited at chromosome ends through interaction with stable constituents of the telomeric structure. In line with this view, it has been shown that TERRA associates with the shelterin components TRF1 and TRF2 (Deng et al., [@B28]). This interaction is mediated by different TRF2 domains, including the amino-terminal GAR domain and carboxy-terminal myb domain (Deng et al., [@B28]). In different studies, a number of other TERRA-binding proteins have been identified, including the heterochromatin protein 1 (HP1), SUV39H1, and MORF4L2, a component of the NuA2 histone acetyltransferase complex (Deng et al., [@B28]; Lopez de Silanes et al., [@B57]; Scheibe et al., [@B77]; Porro et al., [@B70]). Intriguingly, these proteins also localize at telomeres. TERRA transcripts have been proposed to promote or stabilize the recruitment of TERRA-binding proteins at chromosome ends (Deng et al., [@B28]; Arnoult et al., [@B3]; Porro et al., [@B70]). TERRA was also found to interact with tri-methylated histone H3K9me3 and depletion of TERRA molecules associates with a decrease in H3K9m3 and other heterochromatic marks at telomeres (Deng et al., [@B28]). Altogether, this evidence has suggested that TERRA participates in heterochromatin formation at chromosome ends (Figure [1A](#F1){ref-type="fig"}) (Deng et al., [@B28]; Arnoult et al., [@B3]). These findings support the emerging role of TERRA acting as a scaffold molecule to promote recruitment of proteins and enzymatic activities at telomeres.

![**Proposed functions of TERRA at functional and dysfunctional telomeres. (A)** TERRA expression promotes heterochromatin formation at telomeres. TERRA interacts with several proteins at telomeres including TRF2, H3K9me3, origin replication complex 1 (ORC1), HP1, and MORF4L2 proteins. TERRA molecules act as scaffold recruiting chromatin remodeling factors to chromosome ends. **(B)** Expression of TERRA is required for proper capping of telomeres. hnRNPA1 displaces RPA from telomeric single-stranded overhangs. TERRA transcripts interact with hnRNPA1. TERRA-hnRNPA1 interaction removes hnRNPA1 from chromosome ends allowing POT1 to bind the telomeric single-stranded overhangs. **(C)** TERRA participates to DNA damage response triggered by dysfunctional telomeres. Depletion of TRF2 results in dysfunctional telomeres and increased TERRA expression. TERRA interacts with lysine-specific demethylase 1 (LSD1). Elevated TERRA levels in TRF2-depleted cells promote nucleolytic processing of uncapped telomeres by favoring the recruitment of a LSD1-MRE11 complex at telomeres (1). TERRA molecules interact with SUV39H1 histone methyltransferase. TERRA-SUV39H1 interaction promotes H3K9 methylation (H3K9me3) at dysfunctional telomeres and chromosome end-to-end fusions (2).](fgene-06-00143-g0001){#F1}

Connecting telomere biology and genome integrity
================================================

The interaction of TERRA with shelterin components is not the only mechanism through which TERRA molecules can associate with telomeres. Recent evidence has established that endogenous TERRA transcripts can base-pair with their template DNA strand, forming RNA:DNA hybrid structures known as R-loops (Balk et al., [@B8]; Pfeiffer et al., [@B68]; Arora et al., [@B4]; Yu et al., [@B93]). In R-loop structures, the RNA transcript anneals with the DNA template strand, displacing the complementary non-template strand which remains unpaired (Aguilera and Garcia-Muse, [@B1]). R-loops associated with G-rich sequences are involved in transcription termination (Skourti-Stathaki et al., [@B83]) and regulation of gene expression (Ginno et al., [@B41]). Recent findings have revealed the important role of R-loop structures during class switch recombination at the immunoglobulin heavy chains, where R-loops exceeding 1 kilobase in length are detected (Yu et al., [@B92]). While R-loops occur in natural context, they also pose a threat to genome integrity as their formation associates with mutations, recombination, replication stalling, and chromosome rearrangements (Aguilera and Garcia-Muse, [@B1]; Bermejo et al., [@B12]). For this reason, R-loop formation is tightly controlled within the cell and hazardous R-loop structures are removed by the activities of different enzymes such as RNase H (RNase H1 and 2) which degrades the RNA part of a DNA-RNA hybrid (Aguilera and Garcia-Muse, [@B1]); helicases, including Pif1 DNA helicase which is able to unwind DNA-RNA hybrid structures (Boule and Zakian, [@B14]; Paeschke et al., [@B66]); and the THO/TREX protein complex, initially identified for its involvement in transcription and mRNA export (Rondon et al., [@B75]); however, mutants of THO complex accumulate R-loop structures (Huertas and Aguilera, [@B48]).

Recent evidence indicates that R-loops form at telomeres in yeast and in mammalian cells (Balk et al., [@B8]; Pfeiffer et al., [@B68]; Arora et al., [@B4]; Yu et al., [@B93]). In yeast, R-loops are detected at telomeres in WT cells but their formation is repressed by the endogenous RNase H1 and 2 enzymes and by the THO complex. Accordingly, telomeric R-loops accumulate in a RNase H1 and 2 double mutant strain (*rnh1 rnh201*) (Balk et al., [@B8]) as well as in THO complex mutant strains (*hpr1*, *thp2*, and *tho2*) (Pfeiffer et al., [@B68]; Yu et al., [@B93]) (Figure [2A](#F2){ref-type="fig"}). Interestingly, accumulation of telomeric R-loops promotes homologous recombination at telomeres. In particular, a recent study has shown that a telomerase-negative *rnh1 rnh201* yeast strain manifests a higher rate of telomere recombination than WT cells, which translates into a delayed onset of senescence in culture, expected to occur at 60--80 generations in telomerase-negative yeasts (Balk et al., [@B8]). The delay in senescence observed in telomerase-negative *rnh1 rnh201* strain is prevented by inactivation of *RAD52*, an essential regulator of homologous recombination (Wellinger and Zakian, [@B88]; Balk et al., [@B8]). Furthermore, overexpression of *RNH1* decreases telomere recombination and anticipates senescence of telomerase-negative cells (Balk et al., [@B8]). This evidence indicates that telomeric R-loops promote Rad52-mediated homologous recombination among telomeres (Lundblad and Blackburn, [@B60]; Wellinger and Zakian, [@B88]), delaying senescence of telomerase-negative cells (Balk et al., [@B8]). Similar results have been obtained in telomerase-negative THO mutant strains, where accumulation of TERRA at telomeric chromatin and consequent formation of telomeric R-loops promote recombination events among chromosome ends (Yu et al., [@B93]). Interestingly, in telomerase-positive cells, the THO complex also regulates chromosome end processing and prevents interference with telomeric DNA replication by regulating TERRA expression and its association at telomeres (Pfeiffer et al., [@B68]). These findings are consistent with a previous study showing that TERRA overexpression can promote processing of chromosome ends via the 5′--3′ exonuclease Exo1 (Pfeiffer and Lingner, [@B69]).

![**Proposed roles of TERRA in telomere length homeostasis of telomerase-negative and telomerase-positive cells. (A)** In telomerase-negative cells, TERRA molecules form DNA:RNA hybrids, or R-loops, at telomeres. Telomeric R-loop formation is inhibited by RNase H1 and 2, and the THO complex in budding yeast, and is repressed by RNase H1 in ALT cancer cells. Telomeric R-loops promote homologous recombination among telomeres, which maintains telomere length homeostasis in ALT cancer cells and delays senescence of telomerase-negative yeast cells. **(B)** In telomerase-positive yeast cells, TERRA transcripts promote the formation of telomerase clusters at short telomeres in yeast. TERRA expression is induced when a telomere shortens and TERRA transcripts accumulate in a single focus localizing at the nuclear periphery. During S phase, a TERRA focus acts as a scaffold to bind and aggregate telomerase molecules (*TLC1*) into a TERRA/T-Rec cluster. TERRA/T-Rec cluster relocates to the short telomere expressing TERRA to mediate telomere elongation.](fgene-06-00143-g0002){#F2}

In a recent study, Arora and colleagues reported the presence of telomeric R-loops in telomerase-negative human cancer cells (Arora et al., [@B4]). The majority of human tumors reactivate telomerase activity to attain unlimited replicative capacity, but 10--15% of cancers maintain their telomeres in the absence of telomerase (Bryan et al., [@B15]). In these cells, telomere length homeostasis is achieved by homologous recombination-mediated mechanisms which, as in yeast, are known as alternative lengthening of telomeres or ALT (Bryan et al., [@B15]). While homologous recombination events among telomeres are an accepted common feature of ALT processes (Dunham et al., [@B34]; Conomos et al., [@B18]), the mechanisms triggering telomere recombination remain to be defined. Remarkably, Arora and colleagues have shown that ALT telomeres contain telomeric R-loop structures which play an essential role in telomere maintenance of ALT cells (Arora et al., [@B4]). The authors show that telomeric R-loops are tightly regulated by RNase H1, which localizes at telomeres in ALT cells but not in telomerase positive cells. Overexpression of RNase H1 decreases telomere recombination rate and leads to telomere shortening in ALT cells but not in telomerase-positive cells. In line with this evidence, TERRA transcripts localize within ALT-associated PML bodies (APBs) (Arora et al., [@B4]), distinct nuclear bodies of ALT cells where telomere recombination is believed to occur (Yeager et al., [@B90]). TERRA expression is induced in ALT cells (Ng et al., [@B65]; Arora et al., [@B4]) and recent evidence indicate that while TERRA levels decrease from S phase to G~2~ phase in telomerase-positive cancer cells (Porro et al., [@B72]), TERRA foci significantly increase during S phase and G~2~ in ALT cells (Flynn et al., [@B37]). Cell-cycle regulation of TERRA depends on the chromatin-remodeling protein ATRX, which loss or mutation correlate with ALT in human cancer (Heaphy et al., [@B46]; Lovejoy et al., [@B58]; Schwartzentruber et al., [@B80]). Indeed, depletion of ATRX in telomerase-positive cells also results in elevated TERRA levels and persistent TERRA foci in G~2~/M, suggesting that ATRX may act at telomeres by regulating TERRA expression and localization during cell cycle (Flynn et al., [@B37]). Altogether, these findings indicate that TERRA plays a major role in the maintenance of ALT telomeres. Telomeric R-loops thus represent novel players in telomere biology regulating telomere function and telomere stability of ALT cells.

TERRA and DNA damage response at telomeres
==========================================

TERRA transcripts have been proposed to participate in the proper telomere capping that prevents activation of DDR at chromosome ends. During telomeric DNA replication, exposed single-stranded DNA (ssDNA) is bound by the ssDNA binding protein RPA which is required for activation of the ATR checkpoint (Zou and Elledge, [@B95]; Verdun and Karlseder, [@B87]). The shelterin component POT1 acts in repressing ATR-mediated DDR at telomeres and it is believed to antagonize RPA for the binding to the telomeric ssDNA (Denchi and de Lange, [@B24]). *In vitro* evidence suggests that TERRA plays a role in the switch between RPA and POT1 at chromosome ends (Flynn et al., [@B36]). In particular, TERRA directly interacts with hnRNPA1 (Lopez de Silanes et al., [@B57]), which can displace RPA from telomeric ssDNA *in vitro* (Flynn et al., [@B36]). In this scenario, TERRA and hnRNPA1 cooperate to allow POT1 binding to telomeres at the expenses of RPA displacement after DNA replication (Figure [1B](#F1){ref-type="fig"}) (Flynn et al., [@B36]). It will be important to validate this mechanism *in vivo*.

In line with this view, emerging evidence indicates that altered TERRA expression or localization is involved in the activation of DDR at telomeres. Indeed, partial depletion of TERRA expressed from the single telomere 18 in mouse cells leads to DDR activation at different chromosome ends and widespread telomere dysfunction (de Silanes et al., [@B31]). Furthermore, partial down-regulation of TERRA expression (Deng et al., [@B28], [@B29]) and unscheduled accumulation of TERRA transcripts at telomeres associate with activation of DDR at chromosome ends, with consequent formation of "telomere dysfunction-induced foci" (TIF) (Lopez de Silanes et al., [@B57]). Finally, depletion of TRF2, which activates the ATM kinase pathway at telomeres and results in telomere fusions through NHEJ (Takai et al., [@B84]; Denchi and de Lange, [@B24]), leads to up-regulation of TERRA (Caslini et al., [@B16]; Porro et al., [@B70],[@B71]). In this regard, the TRF2 homodimerization domain (TFRH) is required for repression of TERRA transcription (Porro et al., [@B70]). Importantly, this domain is not involved in TERRA binding. The involvement of the TFRH domain in TERRA repression suggests that TRF2 may negatively regulate TERRA transcription through its activity on telomeric structure (Poulet et al., [@B73]; Porro et al., [@B70]). Porro and colleagues recently studied the role of TERRA at dysfunctional telomeres in TRF2-deficient cells (Porro et al., [@B71]). The authors show that TERRA up-regulation correlates with telomeric recruitment of the lysine-specific demethylase 1 (LSD1) (Porro et al., [@B71]). LSD1 directly interacts with TERRA and MRE11 (Porro et al., [@B71]), a subunit of the MRE11/RAD50/NBS1 (MRN) complex required for the resection of the telomeric 3′ overhang to promote chromosome fusion at dysfunctional telomeres (van Steensel et al., [@B86]; Deng et al., [@B26]). Interestingly, TERRA expression stabilizes LSD1-MRE11 association *in vitro* and *in vivo* (Porro et al., [@B71]). These findings suggest that increased expression of TERRA in TRF2-depleted cells may contribute to the activation of NHEJ by promoting MRE11 activity at uncapped telomeres (Figure [1C](#F1){ref-type="fig"}) (Porro et al., [@B71]).

In addition to their implication in telomere end processing, a recent study indicates that TERRA transcripts can promote changes in chromatin structure of uncapped telomeres (Porro et al., [@B70]). In particular, TERRA was shown to interact with the histone methyltransferase SUV39H1 and promote methylation of histone H3K9 upon TRF2 depletion by enhancing telomere association of SUV39H1. SUV39H1 is important for efficient end fusions of TRF2-depleted telomeres (Bartocci et al., [@B9]; Porro et al., [@B70]). Furthermore, accumulation of H3K9me3 at uncapped telomeres may serve as a docking site for the recruitment of the Tip60/KAT5 acetyltransferase, which is required for ATM acetylation and activation (Murr et al., [@B63]; Porro et al., [@B70]). Importantly, TERRA up-regulation upon TRF2 depletion occurs independently of the DDR and it seems to be an early event occurring in parallel or upstream of ATM activation (Porro et al., [@B70]). These findings indicate that TERRA can actively participate in the DDR triggered by dysfunctional telomeres by promoting the association of telomere end processing and chromatin remodeling factors at telomeres (Figure [1C](#F1){ref-type="fig"}).

TERRA and telomerase
====================

Ever since the discovery of TERRA, it was presumed that TERRA transcripts can regulate telomerase activity (Schoeftner and Blasco, [@B78]). The 3′ end of TERRA is indeed complementary to the template region of telomerase RNA and telomerase associates with TERRA transcripts *in vivo*, although it is not known if TERRA binds the template region of hTR (Redon et al., [@B74]). TERRA-mimicking oligonucleotides inhibit telomerase activity *in vitro* (Schoeftner and Blasco, [@B78]; Redon et al., [@B74]). Nevertheless, a role for TERRA as negative regulator of telomerase *in vivo* is still unclear, since overexpression of TERRA has no effect on telomerase activity in human cancer cells (Farnung et al., [@B35]). In yeast, TERRA expression is induced by telomere shortening and TERRA molecules organize telomerase activity at their telomere of origin by acting as a scaffold to promote telomerase nucleation and formation of telomerase recruitment clusters (or T-Recs) (Figure [2B](#F2){ref-type="fig"}) (Gallardo et al., [@B40]; Cusanelli et al., [@B20]). Accordingly, TERRA interacts with yeast telomerase RNA *TLC1 in vivo* and TERRA/T-Recs complexes preferentially localize to TERRA-expressing short telomeres (Cusanelli et al., [@B20]). Further studies *in vivo* will be required to understand the role of TERRA in the regulation of telomerase in mammalian cells.

Concluding remarks
==================

It has become increasingly clear that TERRA transcripts actively participate in the various functions of telomeres and in telomere stability. Their expression and localization must be kept in check as TERRA can contribute by different means to the DDR triggered at dysfunctional telomeres, which poses a threat to genome integrity. Beside a role for TERRA in tumor cells, telomere dysfunction also occurs during replicative senescence (d\'Adda di Fagagna et al., [@B21]), suggesting that TERRA may play a role in aging and age-related diseases. Dysfunction in TERRA expression is linked to diseases, like the immunodeficiency, centromere instability, and facial anomalies (ICF) syndrome, a rare autosomal recessive immune disorder caused by mutations in the DNA methyltransferase gene DNMT3b (Xu et al., [@B89]). TERRA is overexpressed in primary cells of ICF patients, possibly due to the hypomethylated state of their subtelomeric promoters (Yehezkel et al., [@B91]; Deng et al., [@B27]). Other diseases, like telomeropathies, may be associated with TERRA mis-regulation.

Major questions are still unanswered in the field and several challenges lay ahead. First and foremost, a well-established system to efficiently deplete total TERRA in cells remains to be developed. Current approaches, using RNAi or antisense oligonucleotides, only partially deplete TERRA levels. As a role for TERRA as a scaffold molecule involved in the recruitment and organization of enzymatic activities at telomeres is emerging, a major challenge will be to determine how these various activities are organized by TERRA according to the state of a telomere (i.e., capped vs. uncapped, short vs. long).

Telomerase is an established key target for cancer therapies (Harley, [@B45]). Yet recent evidence indicates that telomerase-positive tumor cells can develop resistance to telomerase-targeting cancer therapies by engaging ALT-mediated mechanisms (Chen et al., [@B17]; Hu et al., [@B47]). TERRA is induced in human and mouse tumors (Deng et al., [@B30]) and may act as regulator of telomerase (Cusanelli et al., [@B20]). TERRA also plays a major role in telomere length homeostasis in ALT cancer cells through formation of telomeric R-loops (Arora et al., [@B4]). Targeting TERRA in tumor cells may impair telomerase activity while also preventing the development of ALT-mediated resistance mechanisms, making TERRA an attractive therapeutic target.

Conflict of interest statement
------------------------------

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors would like to thank Michael Jantsch for very helpful comments and suggestions on the manuscript. The research leading to these results has received funding from the Mahlke-Obermann Stiftung and the European Union\'s Seventh Framework Program for research, technological development and demonstration under grant agreement no 609431 to EC and the Canadian Institutes of Health Research (CIHR) MOP-89768 to PC.

[^1]: Edited by: Giuseppe Biamonti, Consiglio Nazionale delle Ricerche, Italy

[^2]: Reviewed by: Michael Chang, European Research Institute for the Biology of Ageing, Netherlands; Antonio Porro, University of Zurich, Switzerland

[^3]: This article was submitted to Cancer Genetics, a section of the journal Frontiers in Genetics
